Prevalence of HIV-1 infection and associated characteristics in a Brazilian indigenous population: a cross-sectional study

Imagem de Miniatura
Arquivos
art_SCHNAUFER_Prevalence_of_HIV1_infection_and_associated_characteristics_in_2023.PDF (915.22 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
SCHNAUFER, Erica C. S.
BARBOSA, Marcelo S.
MARQUES, Michele F. R.
BRITO, Gabriel T.
FERREIRA, Tiago S.
RIBEIRO, Anny D. C.
VALIENTE, Anna C.
GONCALVES, Crhistinne C. M.
TANAKA, Tayana S. O.
Citação
LANCET REGIONAL HEALTH-AMERICAS, v.25, article ID 100562, 11p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Despite significant progress in the areas of prevention, diagnosis, and treatment, HIV continues to result in a substantial number of fatalities on a global scale each year. Gaining insights from epidemiological data can prove instrumental in the development of health promotion strategies, particularly within vulnerable populations, such as indigenous groups. Consequently, our study aimed to investigate the prevalence of HIV infection within the indigenous population residing in the second-largest region of Brazil. Additionally, we sought to explore the subtypes of HIV-1 and detect any drug-resistance mutations present within this population.Methods In this cross-sectional study, we aimed to evaluate the prevalence of HIV-1 infection and explore its associated characteristics within the indigenous population residing in the villages of Jaguapiru and Bororo, located in the Dourados area of Mato Grosso do Sul (MS), Brazil. Blood samples were collected for rapid HIV screening, serological tests, nucleic acid amplification, and HIV subtyping. Additionally, the HIV-1 viral load and CD4+ T lymphocyte count of the people living with HIV (PLHIV) were assessed at the time of recruitment and 24 weeks later.Findings Out of the 2190 invited individuals, 1927 (88%) were included in this study. The average age of the participants was 34.2 (& PLUSMN;13.8) years, with a majority of 74% being female. Moreover, 68.44% of the participants identified themselves as belonging to the Guarani-Kaiowa ethnic group. HIV seroprevalence was 0.93% (18/1927), and 73.22% (1411/1927) were unaware of their serological status. The prevalence of HIV-1 was higher in single indigenous people [10/617 (1.62%)], who received government benefits [14/1021 (1.37%)], had less than five years of formal education [11/685 (1.61%)], had sexual intercourse with users of injectable drugs [2/21 (9.52%)], with history of sexually transmitted infections (STIs) [10/62 (16.2%)] and incarceration [3/62 (4.84%)]. Of 18 positive samples, 44.4% (8/ 18) were successfully amplified, and HIV-1 subtype C was prevalent. Furthermore, we identified HIV-1 drug resistance mutations in four patients, specifically from the classes of Protease Inhibitor, Nucleoside Reverse Transcriptase Inhibitor, and Non-Nucleoside Reverse Transcriptase Inhibitor. Notably, three of these patients exhibited a high viral load even after 24 weeks of undergoing antiretroviral therapy. Out of the 18 PLHIV, 66.66% (12/18) had a viral load below 1000 copies/mL, while 50% (9/18) had a CD4+ T lymphocytes count greater than 350 cells/mL after 24 weeks of treatment.Interpretation Despite the concerted efforts to control HIV infection, the prevalence observed in the indigenous popu-lation under study surpassed that reported in other Brazilian indigenous groups. This disparity highlights the dispro-portionate impact of the disease on this particular group. The detection of drug-resistance mutations further emphasizes the critical need to expand diagnostic coverage, closely monitor treatment strategies, and maintain ongoing molecular surveillance. These measures are imperative for enhancing HIV management within this vulnerable population. Funding This study was partially funded by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUN-DECT), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Secretaria do Estado de Saude (SES) of Governo do Estado de Mato Grosso do Sul, and Universidade Federal da Grande Dourados (UFGD). Copyright & COPY; 2023 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
Palavras-chave
Human immunodeficiency virus, Vulnerable population, Sexually transmitted infections
URI
https://observatorio.fm.usp.br/handle/OPI/56234
Referências
  1. Cardona-Arias JA, 2020, HIV AIDS-RES PALLIAT, V12, P381, DOI 10.2147/HIV.S259792
  2. Benzaken A, 2012, SEX TRANSM INFECT, V88, P294, DOI 10.1136/sextrans-2011-050309
  3. Brasil Ministerio da Saude, 2021, B EP HIV AIDS 2020
  4. Brasil Ministerio da Saude, 2018, MAN TECN DIAGN INF P
  5. Brasil Ministerio da Saude, 2018, PROT CLIN DIR TER MA
  6. Brasil Ministerio da Saude, 2022, B EP HIV AIDS 2022
  7. Brasil Ministerio da Saude, 2018, AG ESTR AMPL AC CUID
  8. Browne AJ, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1707-9
  9. Campbell AR, 2020, DEV CULTURALLY SAFE
  10. Chendi BH, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3824-7
  11. Davy C, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0450-5
  12. Delatorre E, 2017, AIDS RES HUM RETROV, V33, P68, DOI [10.1089/aid.2016.0159, 10.1089/AID.2016.0159]
  13. Etemad B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01749
  14. Gifford RJ, 2009, BIOINFORMATICS, V25, P1197, DOI 10.1093/bioinformatics/btp134
  15. Günthard HF, 2014, JAMA-J AM MED ASSOC, V312, P410, DOI 10.1001/jama.2014.8722
  16. Huang XJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01458
  17. Kops NL, 2019, BRAZ J INFECT DIS, V23, P274, DOI 10.1016/j.bjid.2019.06.009
  18. Liu TF, 2006, CLIN INFECT DIS, V42, P1608, DOI 10.1086/503914
  19. Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
  20. Luft LM, 2011, INT J INFECT DIS, V15, pE661, DOI 10.1016/j.ijid.2011.05.013
  21. Milloy MJ, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20617
  22. Negin J, 2015, AIDS BEHAV, V19, P1720, DOI 10.1007/s10461-015-1023-0
  23. Orellana ER, 2013, QUAL HEALTH RES, V23, P1240, DOI 10.1177/1049732313502129
  24. Tanaka TSO, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00020
  25. Pereira Gerson Fernando Mendes, 2019, Rev. bras. epidemiol., V22, pe190001, DOI 10.1590/1980-549720190001.supl.1
  26. Ponce P, 2017, SALUD COLECT, V13, P537, DOI 10.18294/sc.2017.1120
  27. Russell NK, 2019, REV PANAM SALUD PUBL, V43, DOI 10.26633/RPSP.2019.17
  28. SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
  29. Ssekalembe G, 2020, HIV AIDS-RES PALLIAT, V12, P47, DOI 10.2147/HIV.S231173
  30. TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023
  31. Terras Indigenas do Brasil, 2013, RES IND DOUR MS
  32. UNAIDS, 2019, UNAIDS JOINT UN PROG
  33. Ward J, 2018, LANCET HIV, V5, pE506, DOI 10.1016/S2352-3018(18)30135-8

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/50
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/05